Comparative Pharmacology
Head-to-head clinical analysis: ATIVAN versus CENTRAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATIVAN versus CENTRAX.
ATIVAN vs CENTRAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.
10-30 mg orally, 3-4 times daily.
None Documented
None Documented
Terminal elimination half-life is 12–18 hours (mean ~14 h). In elderly, hepatic impairment, or obesity, half-life may be prolonged up to 30 hours.
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Renal: lorazepam is primarily excreted as inactive glucuronide conjugates; <1% is excreted unchanged. Total: ~95% excreted in urine, ~5% in feces.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Category C
Category C
Benzodiazepine
Benzodiazepine